

MARTA ROMÁN MORENO

E-mail: marta.romanmoreno@ucsf.edu

Phone: (+1) 4158670450 ; (+34) 626634688

Address: 1500 4th St (UCSF, Rock Hall Building), San Francisco, CA 94158

ACADEMIC EDUCATION

2015 – 2019: PhD in Biomedical Research, Science Faculty, Center for Applied Medical Research (CIMA), Pamplona (Spain).

2017 - 2018: Master's Degree in Teaching Secondary Education (Biology), International University of La Rioja (UNIR), Logroño (Spain).

2014 – 2015: Master's degree in Biomedical Research, Science Faculty, University of Navarra, Pamplona (Spain).

2010 – 2014: Degree in Biochemistry, University of Granada, Granada (Spain).

LANGUAGES: Spanish (native); C1 Advanced English level (Cambridge ESOL)

COUSES AND DIPLOMAS:

2021: Introduction to Evidence-Base Pedagogy, University of California, San Francisco, USA.

2020: Introduction and Intermediate R programming, DataCamp.

2016: Young Entrepreneurship Program YUZZ, CISE.

2015: Entrepreneurship (Iniciativa Emprendedora), EOI.

2015: General training focused on teaching, University of Navarra, Spain.

2014: Category B for animal handling, University of Navarra, Spain.

GRANTS

2021-2022: Postdoctoral fellow Fundación Ramón Areces (Spain).

2016 – 2019: PhD fellow FPU (University Teacher Training), Ministry of Education, Culture and Sport (Spain).

2018: Research Mobility fellow FPU, Ministry of Education, Culture and Sport (Spain).

2015 – 2016: PhD fellow ADA (Asociación de Amigos), University of Navarra (Spain).

2013 – 2014: Collaboration grant in the Department of Radiology and Physical medicine (University of Granada) Ministry of education, culture and sport, (Spain).

PROFESSIONAL EXPERIENCE

Research

02/2020 – Today: Postdoctoral Scholar in the Department of Pediatrics at the University of California in San Francisco (UCSF), San Francisco (USA).

09/2019 – 12/2019: Postdoctoral position at Center for Applied Medical Research (CIMA), Pamplona (Spain).

09/2015 – 09/2019: PhD in Biomedical Research, Science Faculty, Center for Applied Medical Research (CIMA), Pamplona (Spain).

04/2018 – 07/2018: International doctoral secondment. Gustave Roussy Cancer Institute, Paris (France)

03/2015: International master secondment, University Hospital Zurich, Zurich (Switzerland).

05/2012 – 06/2014: Degree practices, University of Granada, Granada (Spain).

Teaching

01/2021 – Today: Part-time teaching position at University of San Francisco (USF), Department of Biology, San Francisco, CA (USA)

02/2016 – 09/2019: Associate professor in the Department of Pathology, Anatomy and Physiology at the University of Navarra, Pamplona (Spain).

12/2017 – 03/2018: Biology and Math teacher in practices at the High School for Adults “Félix Urabayen”, Pamplona (Spain).

11/2015: Teaching assistant in the Course Cancer Cytogenetics (Master in Biomedical Research) at the University of Navarra, Pamplona (Spain).

SCIENTIFIC PRODUCTION

PUBLICATIONS:

Baraibar, I.*, Roman, M.*, *et al.* (2020). Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of KRAS-mutant Lung Cancer by Stimulating PD-L1 Expression and Tumor Infiltrating CD8+ T Cells. *Cancers*, 12(11), 3169. <https://doi.org/10.3390/cancers12113169>

Valencia K, *et al.* (2019) The mir181ab1 cluster promotes kras-driven oncogenesis and progression in lung and pancreas. *The Journal of clinical investigation*, 130(4), 1879–1895. <https://doi.org/10.1172/JCI129012>.

Román, M., *et al.* (2019). Inhibitor of Differentiation-1 Sustains Mutant KRAS-Driven Progression, Maintenance, and Metastasis of Lung Adenocarcinoma via Regulation of a FOSL1 Network. *Cancer Research*, 79(3), 625-638.

Román, M., *et al.* (2018). KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target. *Molecular cancer*, 17(1), 33.

Castañón, E., *et al.* (2017). The inhibitor of differentiation-1 (Id1) enables lung cancer liver colonization through activation of an EMT program in tumor cells and establishment of the pre-metastatic niche. *Cancer letters*, 402, 43-51.

Baraibar, I., *et al.* (2017). Pazopanib-induced asymptomatic radiological acute pancreatitis: A case report. *Molecular and clinical oncology*, 6(5), 651-654.

Fernández, M. F., *et al.* (2014). Endocrine disruptors: time to act. *Current Environmental Health Reports*, 1(4), 325-332.

PARTICIPATION IN I+D+i PROJECTS:

12/2017 – 12/2020: *Nueva estrategia terapéutica para evitar el escape inmune en cáncer de pulmón metastásico mediante el bloqueo combinado de PD-1 e Id1.* PI: Ignacio Gil Bazo. DEPARTMENT OF HEALTH, GOVERNMENT OF NAVARRA, SPAIN. (90,000€)

06/2017 – 05/2020: *Nueva estrategia terapéutica para evitar el escape inmune en cáncer de pulmón metastásico mediante el bloqueo combinado de PD-1 e Id1.* PI: Ignacio Gil Bazo. MERC GROUP, SPAIN. (30,000€)

01/2016 – 12/2018: *Estudio pronóstico y predictivo de células tumorales circulantes (CTC) en adenocarcinoma de pulmón. Valoración in vivo del papel de ID1 e ID3 en la capacidad metastática de las CTC.* PI: Ignacio Gil Bazo. INSTITUTO DE SALUD CARLOS III (FIS), SPAIN. (92,560€)

09/2015 – 05/2016: *Estudio in vivo e in vitro de la variante alternativa de corte y empalme del ARN mensajero del receptor de andrógenos V7 en pacientes con cáncer de próstata sensible y resistente a castración tratados con Enzalutamida y/o Acetato de Abiraterona e impacto sobre la eficacia del tratamiento.* PI: Ignacio Gil Bazo. CAJA NAVARRA FOUNDATION. SPAIN. (30,000€).

PARTICIPATION IN CONFERENCES:

Marta Roman *et al.* *Functional analysis of the role of RAP1GDS1 and RhoA in KRAS-driven LUAD.* The Third RAS Initiative Symposium (2021). Online conference. Poster Presentation. International conference.

Marta Román *et al.* *Functional analysis of the role of RAP1GDS1 and RhoA in KRAS-driven LUAD.* UCSF BMS retreat (2020). Online conference. Poster Presentation.

Marta Román Moreno *et al.* *The role of Id1 in tumor progression and liver metastasis in a KRAS-driven lung cancer model.* Liver Metastasis Research Network (2019). Valencia, Spain. Oral communication. International conference.

Marta Román Moreno *et al.* *Inhibitor of differentiation-1 (Id1) sustains mutant KRAS-driven lung adenocarcinoma (LUAD) via regulation of a FOSL1 network.* Jornadas De Formación CIBERONC-CIBERES (2018). Madrid, Spain. Oral communication. National conference.

Marta Román Moreno *et al.* *The critical role of Inhibitor of differentiation-1 (Id1) sustains mutant KRAS-driven lung adenocarcinoma (LUAD).* 16th ASEICA International Congress (2018). Valencia, Spain. Poster Presentation. International conference.

Ignacio Gil Bazo *et al.* *PD-1 and Id-1 Combined Blockade Impacts Tumor Growth and Survival Through PD-L1 Expression and Tumor Infiltration by Immune-Related Cells.* IASLC 19th World Conference on Lung Cancer (2018). Toronto, Canada. Oral communication. International conference.

Alfonso Calvo Gonzalez *et al.* *Anti-PD-1 and anti-Id-1 combo impacts tumor response and survival by increasing tumor immune-related cells in lung cancer.* ASCO 2018 Annual Meeting (2018). Chicago, Illinois. Poster presentation. International conference.

Marta Román Moreno *et al.* *El papel preventivo y terapéutico de la inhibición de Id1 en adenocarcinoma de pulmón (ADP) con mutación en KRAS (KM).* XVII Congreso SEOM (2017). Madrid, Spain. Poster Presentation. National conference.

Iosune Baraibar Argota *et al.* *Recuento de linfocitos y neutrófilos tras dos ciclos de tratamiento y expresión de TTF1 como predictor precoz de respuesta a tratamiento de inmunoterapia (IT) en pacientes con cáncer no microcítico de pulmón (CNMP) metastásico.* XVII Congreso SEOM (2017). Madrid, Spain. Poster Presentation. National conference.

Iosune Baraibar Argota *et al.* *Lymphocytes and neutrophils count after two cycles and TTF1 expression as early outcome predictors during immunotherapy.* IASLC 18th World Conference on Lung Cancer (2017). Yokohama, Japan. Poster Presentation. International conference.

Marta Román Moreno *et al.* *Preventive and Therapeutic Action of Id1 Inhibition in KRAS-Mutant (KM) Lung Adenocarcinoma (LAC) Tumors in a Xenograft Murine Model.* IASLC 18th World Conference on Lung Cancer (2017). Yokohama, Japan. Poster Presentation. International conference.

Marta Román Moreno *et al.* *High chemopreventive and therapeutic efficacy of Id1 Inhibition in KRAS-mutant (KM) adenocarcinoma (AD) non-small cell lung cancer (NSCLC).* ESMO 2017 European Society of Medical Oncology (2017). Madrid, Spain. Poster Presentation. International conference.

Iosune Baraibar *et al.* *Lymphocytes and neutrophils count after two cycles and TTF1 expression, as early outcome predictors during immunotherapy (IT) in stage IV non-small cell lung cancer (NSCLC) patients.* ASCO 2017 Annual Meeting (2017). Chicago, Illinois. Poster Presentation. International conference.

Marta Román Moreno *et al.* *El silenciamiento génico de id1 e id3 aumenta la supervivencia y reduce la tasa de metástasis hepáticas (MH) en adenocarcinoma de pulmón (ACP) KRAS mutado (KM).* XVI Congreso SEOM SEOM (2016). Madrid, Spain. Oral communication. National conference.

Marta Román Moreno *et al.* *Inhibitor of differentiation 1 (Id1) and 3 (Id3) genes confer poor prognosis in KRAS-mutant (KM) lung adenocarcinoma (LA) patients. Gene silencing reduces metastatic rate to the liver (LM) and increases survival.* ESMO 16 European Society of Medical Oncology (2016). Copenhagen, Denmark. Poster Presentation. International conference.

Marta Román Moreno *et al.* *Inhibitor of differentiation 1 (Id1) and 3 (Id3) genes confer poor prognosis in KRAS-mutant (KM) lung adenocarcinoma (LA) patients. Gene silencing reduces metastatic rate to the liver (LM) and increases survival.* RTICC (2016). Salamanca, Spain. Oral communication. National conference.

PERSONAL STATEMENT

Professional, dedicated, detailed and capable scientist with more than 5 years of experience in cell/molecular biology and biomedicine. Specialized in oncology (basic research, mouse models and knowledge about immunotherapy and liquid biopsy). Extensive experience in a wide variety of laboratory techniques, both basic and those that require a higher level of specialization. Motivated with my daily work, efficient and willing to take on new challenges. Ability to work in teams, patient and decisive. Curious and enterprising. After all the training received during these years, my goal is to position myself differentially in the sector of the biomedicine and academy/university teaching.